01—Abstract
Summary
Summary of the 8-K filed May 7, 2026. Cited figures are marked; the original filing is the authoritative source.
Zoetis (ZTS) reported first quarter 2026 results that came in below management's expectations, with the company citing a more challenging operating environment.
Revenue rose 3% reported to $2.262 billiona but was flat on an organic operational basis. Reported net income was $601 million ($1.42 diluted EPS), while adjusted net income reached $646 million ($1.53 adjusted diluted EPS, up 9% reported and 7% organic operational). The U.S. segment was a clear weak spot, with revenue down 8% driven by an 11% decline in companion animal sales from competitive pressure in dermatology and Simparica Trio, pet owner price sensitivity, lower veterinary visits, generic competition on Convenia and Cerenia, and lower Librela sales.
International revenue grew 17% reported (10% organic operational), and livestock grew 15% reported, partly helped by an estimated $100 millionb benefit from the Fiscal Year Alignment and timing of price increases. Management lowered full-year 2026 guidance. Revenue is now expected at $9.680 to $9.960 billion (2% to 5% organic operational growth), adjusted net income at $2.870 to $2.950 billion (2% to 6% organic growth), and adjusted diluted EPS at $6.85 to $7.00.
Reported diluted EPS guidance is $6.35 to $6.50c. Investors should note that the Fiscal Year Alignment, which eliminated the one-month reporting lag for non-U.S. subsidiaries and retroactively recast prior periods, complicates year-over-year comparisons and flatters International growth in the quarter.
Strategically, Zoetis continues to point to a pipeline of more than 12 potential blockbusters and a planned acquisition of Neogen's animal genomics business, expected to close in the second half of 2026. Restructuring and certain significant items totaled $27 milliond pre-tax in the quarter, primarily employee termination costs tied to organizational refinements, signaling ongoing cost actions alongside the commercial reset.
02—Key points
Key Highlights
- Q1 2026 revenue of $2.262 billion rose 3% reported but was flat on an organic operational basis, indicating limited underlying growth.
- U.S. revenue fell 8% to $1.09 billion, with companion animal sales down 11% due to competition in dermatology and Simparica Trio, price sensitivity, and generic pressure on Convenia and Cerenia.
- International revenue grew 17% reported (10% organic operational) to $1.149 billion, aided by roughly $100 million from the Fiscal Year Alignment and price increase timing.
- Adjusted diluted EPS of $1.53 rose 9% reported, while GAAP diluted EPS of $1.42 rose 6%; adjusted results exclude $27 million of pre-tax significant items and $2 million of acquisition costs.
- Full-year 2026 guidance was revised: revenue to $9.680-$9.960 billion, adjusted diluted EPS to $6.85-$7.00, and reported diluted EPS to $6.35-$6.50, reflecting a weaker operating environment.
- Livestock revenue rose 15% reported (5% organic operational) to $720 million, led by cattle, poultry vaccines, and screwworm-related parasiticide demand.
- Zoetis agreed to acquire Neogen's animal genomics business, expected to close in the second half of 2026, and reported a pipeline of more than 12 potential blockbusters.
03—Questions
Frequently Asked Questions
Why did Zoetis lower its 2026 guidance?
Management said the first quarter unfolded in a more challenging environment than anticipated. Pet owners showed greater price sensitivity, veterinary visits declined, demand for premium innovative products softened, and competition intensified in dermatology and parasiticides. The revised guidance reflects these trends, and the company is pursuing commercial execution changes and cost discipline.
How much of the International growth is real versus accounting-driven?
Part of it is not organic. The Fiscal Year Alignment, which removed the one-month reporting lag for non-U.S. subsidiaries, contributed an estimated $100 million to Q1 International revenue, driven by price increase timing, delayed order processing from late 2025, and a weak Q4 2024 comparison. Organic operational International growth of 10% should be read with this benefit in mind.
What is driving the decline in the U.S. business?
U.S. companion animal sales fell 11%, reflecting heightened competition in the key dermatology franchise and Simparica Trio, macroeconomic price sensitivity among pet owners, generic competition for Convenia and Cerenia, and lower Librela sales. U.S. livestock sales partly offset this, rising 7%.
Are reported and adjusted results materially different, and what is excluded?
Yes, though the gap is modest. Q1 adjusted net income of $646 million exceeds GAAP net income of $601 million by $45 million, which excludes purchase accounting adjustments ($21 million after tax), acquisition-related costs ($1 million after tax), and certain significant items ($23 million after tax), mainly employee termination costs and business process transformation expenses. Investors should weigh whether these items recur.
What does the pending Neogen genomics acquisition mean for Zoetis?
Zoetis plans to acquire Neogen's animal genomics business to strengthen its livestock genetics and predictive insights capabilities. The company expects the deal to close in the second half of 2026. The filing does not disclose the purchase price or expected financial impact in this document.
04—Continue